Abstract
Background and objectives COVID-19 can either cause death or go unnoticed but antibodies will remain protecting us of SARS-CoV-2 reinfection for an uncertain time and to a uncertain extent. Knowledge of COVID-19 epidemiological and hematological features should help make a good forecast of resources for possible future outbreaks or vaccination strategies, and would facilitate decisions in the social sphere by a more reliable estimate of the percentage of immunized individuals. Our aim was to describe seroprevalence evolution from summer 2019 to autumn 2020 in Spain and to determine its relationship with age, blood group or haematological parameters.
Materials and methods Sera and plasma from historical donation archives were randomized and a total of 12,718 samples tested by a Chemiluminiscent analysis for anti SARS-CoV-2 N protein total immunoglobulins. Blood donors were 60.9% males, average age 46+/-13. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings.
Results 6.7% donors were positive by the end of 1st wave. No differences by sex, age or blood group were found regarding antibodies. Leukocyte and neutrophil counts were lower (p<0.001) and haemoglobin was lower (p<0.001) in positive donations than in negative ones. Sex differences were found in neutrophils, leukocytes, haemoglobin and haematocrit as related to SARS-CoV-2 antibodies.
Conclusions Seroprevalence due to asymptomatic cases would be slightly lower than the overall one due to age restrictions for blood donors. Sex and age would not affect COVID-19 susceptibility but its severity. Gender differences would be present in asymptomatic individuals. Further studies are needed to confirm these gender differences as they can help better understand the immune response to COVID-19, its pathogenesis and prognosis.
Introduction
Most SARS-CoV-2 infection cases develop an effective immune response during infection. Even these who curse asymptomatic or with just mild symptoms mount humoral or cell responses. This makes it hard to calculate accurate infection or fatality rates and prevalence [1]. Immunization either due to infection or to vaccination leads to viral eradication and to specific T cell responses and antibodies against SARS-CoV-2, that usually peak 8–15 days after infection [2]. Antibodies that neutralize the virus are the primary protection against COVID-19, and lymphocyte responses augment protection.
Antibody assays are quite different: they either detect antibodies against different viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin classes: IgG, IgM, IgA or their combinations. It should be noticed that every approved vaccine in Europe to date (May 2020) enhances anti-S responses, whereas an infection leads to a multi specific response to SARS-CoV2 antigens. To make it even messier, many factors can influence test performance, including cross-reactivity with other coronaviruses or platform (laboratory-based vs point-of-care, lateral flow). Chemiluminiscence assays have suitable performances regarding both sensibility and sensitivity while correlation to neutralizing antibodies would be around 0.7 [3].
Our region, Castilla y Leon, with a population of 2.299.598 inhabitants, has accumulated nearly 225.000 COVID-19 confirmed cases (https://analisis.datosabiertos.jcyl.es/), with an overall case-fatality rate of 3.01 to date. Our institution, Centro de Hemoterapia de Castilla y León keeps within its Biobank plasma samples from every single donation along the last ten years, that makes up around one million samples. Any demographic data such as sex or age and laboratory parameters (blood counts, blood group, haemoglobin, etc.…) is as well kept in a database (Hemasoft, eDelphyn).
Blood donor-based serosurveillance is a powerful and cost-effective strategy to monitor infectious diseases. There are quite a lot of infections for which routine donor screening is well known to be useful, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-lymphotrophic virus (HTLV), and West Nile virus (WNV) [1], babesiosis or Crimea-Congo fever. The use of blood donor samples means we’re sampling mainly asymptomatic and recovered cases of COVID-19 (normal blood donation is allowed after 28 days following COVID-19 symptoms’ resolution).
Seroprevalence surveys are then needed to monitor coronavirus pandemic, both before and after vaccination strategies [4]. Reported COVID-19 cases do not represent the full SARS-CoV-2 disease burden due to low detection rates, especially at the beginning of pandemics. Case reports are dependent on patients’ seeking health care, massive local screenings or regional tracking activities. Analysis of data from seroprevalence and serosurveillance is a common strategy for estimating underreporting and real disease burden. There are several features that should be taken into account, including time between infection and antibody development or antibody waning, which must be considered to understand seroprevalence surveys avoiding biases. Any seroprevalence survey should be evaluated for selection bias. Serological surveys with a random sampling design of the general population are difficult to perform in a pandemic, but a random sampling design of the general population yields a seroprevalence estimate least likely to be affected by selection bias. Blood donors are a quite representative subset of general population aged 18-65 and our historical plasma collection was big enough to perform a time-layered randomization.
Heterogeneity of susceptibility and transmission is hard to evaluate but does exist [5]. A portion of the population is not susceptible to infection from the first pathogen contact. Some of them may have pre-existing immunity via cross-reactivity or particular host factors such as mucosal immunity or trained innate immunity protection (as it has been reported to be conferred by DTP or BCG vaccination)[6]. There is as well a proportion of seronegative individuals that will develop immunity by T cell mediated responses but without exhibiting an antibody response [7].
The starting hypothesis is the existence of a certain number of asymptomatic carriers of the SARS-CoV-2 virus that would develop antibodies against it [7] (and subsequently contribute to herd immunity). Those asymptomatic cases were unnoticeable before testing began and might had been circulating from an unknown moment. Early cases have been described in France [8], arising the question of whether the pathogen could have been circulating even before the official recording of the first cases. The main aim of this study was to determine what percentage of the population has had contact with SARS-CoV-2 at different times and has therefore developed antibodies against it. A secondary goal was to describe haematological features of seropositive donors and establish whether sex, age, blood group or haematological abnormalities were related COVID-19 exposure.
Knowledge of COVID-19 epidemiological and hematological features should help make a good forecast of resources for possible future outbreaks or vaccination strategies, and would facilitate decisions in the social sphere by a more reliable estimate of the percentage of immunized individuals.
MATERIAL and METHODS
Aim, design and setting of the study
The aim of this study was to analytically obtain, a reliable knowledge of asymptomatic COVID-19 cases and their immunological and haematological characteristics, seroprevalence, rate of positive donations and its temporal evolution along the first wave in Spain. So, a retrospective observational analysis was performed.
Participants
The Biobank is included in the National Registry of Biobanks (RD17 / 16/2011) with the number B.0000264. The institution holds an ISO 9001: 2015 certification endorsing our granting of safety and traceability of any human biological sample we distribute, always behaving Spanish and European rules on human samples and data protection management.
The study population comprised randomised plasma-EDTA and serum frozen samples from blood, plasma (excluding convalescent) and platelet donations from July 2019 to October 2020. Donations collected since 19/07/2019 (week - 24) to 19/10/2020 (week 43) were randomized to select a minimum of 150 donations per week. A total of 12,718 samples of 11,444 donors over 18 years old were included.
Laboratory data and analyses
All haematological and demographic data were extracted from electronic database eDelphyn (Hemasoft). Variables analyzed included age, sex, blood group, and laboratory data.
Major laboratory markers were extracted from our donation database. Routine blood examinations included leukocyte (WBC), neutrophil, lymphocyte, platelet, monocyte, eosinophil and basophil counts (cells*103/µL) and their percentages. Serum immunoglobulins IgG, IgA and IgM (mg/dL), haemoglobin (Hb), haematocrit (HCT) and corpuscular mean volume were analysed as well.
An automated chemiluminiscence double-antigen sandwich immunoassay for the in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human serum and plasma was performed. The target antigen of this immunoassay is a recombinant nucleocapsid (N) protein. Elecsys® Anti-SARS-CoV-2 (Roche, Basel, Switzerland) detects antibodies correlating with virus-neutralizing ones and is therefore useful to help characterize the immune reaction to SARS-CoV-2 [9, 10]. Immunoassay was validated by our serology lab by testing of 6 pairs of samples (plasma EDTA and serum) from diagnosed PCR-positive, symptomatic cases infected by mid-April, that were previously reported positive by the Spanish National Microbiology Centre, and checked to be as well positive for IgG (Chemiluminiscence, N protein, Abbott Alinity S, Chicago USA) and IgA (ELISA, S protein, Euroimmunn, Lübeck, Germany) antiSARS-CoV-2. Another set of ten prepandemic samples, therefore supposed to be negative, were equally analyzed. A 100% concordance was yielded by these validation assays. The cut-off was that recommended by manufacturer (OD>1 to report reactivity). Researchers performing anti SARS-CoV-2 analyses were blind to the condition of COVID-19 convalescence and to any other characteristic of the donors or to the donation dates.
Statistical analysis
Demographic and clinical characteristics of patients are expressed as their mean and standard deviation (SD) for continuous variables and frequency distributions are reported for categorical variables. Age was analysed both as continuous and categorical variable; in the latter case was recoded into 4 groups: <30, 30-45, 45-60, 60-75 years old.
Kolmogorov-Smirnov test was performed on each continuous variable to contrast normality. Only IgG and IgM serum levels followed normal distributions, therefore non-parametric Mann-Whitney U test was performed to compare laboratory values. To contrast the hypothesis of independence within categorical variables, Pearson’s Chi-square and Fisher’s exact test were carried out. All tests were calculated with a confidence level of 0.05.
Results
A total of 12,718 randomized donations (either whole blood, plasmapheresis or platelet apheresis) were tested for total anti SARS-CoV2 antibodies. Donors made up 11,444, 60.91% males, aged 18-75, average 46+/-13, 45.8% A, 40.3% O, 10.56% B, 3.31% AB.
Seropositivity rate grew up from week 11 to week 25, reaching a 11.1% peak, with just subtle descents until week 43 when 2nd wave arose in our country. Plateau was reached by the last week of May 2020, 11 weeks after close lockdown in Spain (that begun in March, 15th) and 17 weeks after 31/01, the date of the first declared case in or country. 660 out of 9,886 single donors were positive within weeks 11 to 43, that makes a seroprevalence of 6.73% at the end of the first wave.
Three 2019 donations were reactive (from July, September and October) but none of them were positive when testing separately IgG, IgA or IgM. Their ODs were 1.05, 1.08 and 5.46 respectively. 1,142 donations from year 2019 were analyzed.
No differences in anti SARS-CoV2 reactivity due to sex, age or blood group of donors were found (Table 1).
Immunoglobulin levels didn’t show any differences as comparing positive and negative donations. Haemoglobin (14.9 vs 14.7 g/dL; p<0.001) and haematocrit (45.2% vs 44.4%;p<0.001) were both significantly lower in positive donations . Leukocyte count (WBC) was as well slightly lower (7.23 vs 7.06 cells*103/µL; p=0.026) (Table 2). A trend was found of lower number of neutrophils (4.3 vs. 4.2 cells*103/µL; p=0.117), lower count of monocytes (0.46 vs. 0.45 cells*103/µL; p=0.117) and higher percent of basophils (0.49% vs 0.51%; p=0.131).
As layering data by sex (Table 3), the fact arose that haematocrit (46.8% vs 45.9%; p<0.001) and haemoglobin (15.5 vs 15.3 g/dL; p<0.001) were significantly lower just in males and that positive females had significantly less WBC (7.67 vs 7.25 cells*103/µL;p=0.027) and neutrophil numbers (4.53 vs 4.27 cells*103/µL;p=0.014).
Some trends were found as well related to sex. Regarding positive women neutrophil percent would be lower (59.4% vs 58.10% p=0.065), with a higher lymphocyte percent (31.7% vs 33.10%; p=0.074) a lower platelet count (261 vs 255 cells*103/µL; p=0.152), monocyte count (0.46 vs 0.44 cells*103/µL; p=0.132) and basophil percent (0.5% vs 0.4%; p=0.060). Anaemia was more frequent in positive male donors as (6.1% vs 9.6%; p=0.031), A trend of. No other significant differences were found either in males, females or overall. Figure 2 summarize these findings.
Discussion
A slightly lower seroprevalence than that found in general population was found among blood donors without COVID-19 antecedents. The 6.73% seroprevalence we found is a little lower than that reported in the seroprevalence study ENE-COVID-19 promoted by the Instituto Nacional the Epidemiología [11], where it is reported that a 7.2% of the participants in our region would have anti SARS-CoV2 IgG antibodies by the end of June 2020. Almost one quarter people in our region (25.51% according to National Institute of Statistics, INE 2020 data) is older than 65 and elderly are necessarily underrepresented in this study as it comprises blood donors. That happens as well with population aged less than 18 (under 4.5% in our region). One limitation of this study is that of age, restricted to 18-75 years old, but it would make just a little difference of 0.5% in seroprevalence estimation. Immunization rate would be a bit higher regarding the fact that some individuals do not exhibit antibodies but still mount an efficient specific T-cell response [2]
Perhaps the main strength of our study is the large number of samples we randomized and tested along almost one year. The first recorded COVID-19 case in Spain was reported on 31/01/2020, but 3 positive donations were found as testing samples collected along 2019. That could be meaningful in two opposite ways: one possible explanation would be cross reactivity to seasonal cold coronaviruses and the other would be that SARS-CoV-2 might have been circulating at least since 2019 summer.
It is now known that up to 28% people would have protection against SARS-CoV-2 due to cross reaction to other coronaviruses [2]. It has been checked that long-term cross-reactive both T-cell and antibodies can be a correlate of protections against COVID-19 [12].Asymptomatic or mild cases couldn’t be diagnosed or reported until the first tests were developed in the first term of 2020. There are other reports about SARS-CoV-2 circulating in Europe along 2019. Italy’s Ministry of Health reported high levels of unusual strains of flu and pneumonia concentrated in the area around Milan and appearing in 17 of Italy’s 20 regions [13]. Our three 2019 positive donors would be even earlier cases, but the simplest explanation would be that of cross reaction. In fact, we cannot 100% ascertain whether some of the positives along the period of study might be cross reactions as well or both reactive due to SARS-CoV-2 infection together with previous coronavirus immunity.
Conversely to clinical forms of COVID-19 [14,15] neither age nor sex have an influence on the probability to develop an asymptomatic COVID-19 infection in our cohort. Several smaller seroprevalence reports from European countries support this feature [16-20]. It may be therefore ascertained that age and sex do not have a role in SARSCoV-2 infection susceptibility, but only in their progression to severe forms.
Blood group has been reported elsewhere [7,21-23] to confere susceptibility or determine severity of SARS-CoV2 infection. Most studies do not separate susceptibility and severity. It should be noticed that there are no large studies characterizing asymptomatic cases in literature, perhaps this is one of the reports comprising more asymptomatic individuals. Relationship of ABO system with susceptibility is not supported by our data. We excluded convalescent plasma donors, opposite to other studies, that focused into these asymptomatic positive donors [22]. Perhaps blood group might be related only to symptomatic cases and would be therefore related to severity but not related to asymptomatic SARS-CoV-2 infection. Another surface antigens such as HLA or KIR might be as well involved and should be studied.
Several blood count anomalies have been reported to be associated to SARS-CoV2 infection, notably lymphopenia and neutrophilia are related to severest forms [24]. Our data conversely reveal that asymptomatic positive women had a significant lower count of WBC and neutrophils as compared to negative ones. Similar low counts of WBC and neutrophils have been reported in young (<19) cohorts, comprising mainly mild and asymptomatic cases [25]. Perhaps this feature might be therefore a correlate of mildness. Elevation of monocytes have been elsewhere reported in short series of mild cases [26]. Our observation in will be in the same line of those findings but a gender bias cannot be discarded so far seropositive women would go in the opposite direction.
Several reports about haemolytic anaemia secondary to SARSCoV-2 have been published [27-30]. We cannot discard the possibility of a mild silent haemolytic anaemia in asymptomatic cases. Again, little analysis of asymptomatic cases is available by the moment.
We can conclude that seroprevalence estimations through blood donation analysis resemble data obtained from population-based surveys. Sex and age would not affect COVID-19 susceptibility but its severity. Gender differences are present even in asymptomatic individuals: females are known to develop milder COVID-19, this fact might be related to a lower WBC count whereas positive males although asymptomatic, present anaemia more frequently than negative ones. Further studies in large cohorts are needed to confirm these gender differences and to characterize asymptomatic COVID-19 cases as they can help better understand immune response to COVID-19, its pathogenesis and prognosis.
Data Availability
Data collected for the study, including fully anonymized participant data, are available to others. Data available include fully anonymized participant data and data dictionary. Related documents are available from the date of publications henceforth: study protocol, statistical analysis, and approval of Ethical Board. These documents are available from the date of publications henceforth at email address cmartinalo@saludcastillayleon.es. Data would be shared after approval of proposals by the Valladolid Este Ethical Committee.
Availability of data and materials
The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request and after mandatory approval of proposals by the Valladolid Este Ethical Committee
Acknowledgements
LB and MCM conceived and designed the study, NH, NO; MP and AP acquired data, IP, AJ and MIGF performed analysis and interpretation of laboratory data, MCM and LB drafted the article and revised it critically for important intellectual content, all authors provided final approval of the version to be submitted.
The authors thank to all blood donors making this work possible by allowing research use of their samples by the Biobanco del Centro de Hemoterapia y Hemodonación de Castilla y León. They also thank the staff in charge of blood donation, and lab technicians for their efforts and Roche for its support.
Footnotes
Sources of research support This work has been supported by Roche Diagnostics International Ltd., who provided free equipment and test reagents. Roche Diagnostics International Ltd. was not involved, either in study design, collection, analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication.
Ethical considerations This study was conducted according with national regulations, institutional policies and in the tenets of the Helsinki Declaration. This study was approved by the Valladolid Health Area Drug Research Ethics Committee, in a meeting held on June 11, 2020 with the reference number “BIO-2020-93”. Included donors consented to participate in Biobank research activities. The privacy rights of human subjects were always observed.
Figure added and some sentences, mainly within the discussion clarified
Abbreviations
- (IgG)
- Immunoglobulin G
- (IgA)
- immunoglobulin A
- (IgM)
- immunoglobulin M
- (PCR)
- polymerase chain reaction
- (SD)
- standard deviation
- (IQR)
- interquartile range
- (WBC)
- White blood cells
- (Hb)
- haemoglobin
- (HCT)
- haematocrit
- (MCV)
- mean corpuscular volume